GO
Loading...

Henry Waxman

More

  • WASHINGTON, July 9- Members of a U.S. House of Representatives panel disagreed on Wednesday on elements of a bill to rein in companies that demand licensing fees for invalid patents or are otherwise dishonest in writing what are known as "demand letters."

  • Passed by a vote of 266 to 150, the bill must still get through the Senate. Senate Energy Committee head Mary Landrieu, of Louisiana, along with Senator Mark Udall, a Democrat from Colorado, have introduced a similar bill in the Senate that would require a decision within 45 days of FERC's environmental review.

  • DETROIT, June 13- General Motors Co recalled 511,528 Chevrolet Camaros on Friday for an ignition switch problem similar to the defect linked to at least 13 deaths in Chevrolet Cobalts and other models.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • WASHINGTON, April 30- The U.S. House energy committee has approved legislation to limit the length of review time for liquefied natural gas export applications, in a compromise aimed at attracting bipartisan support for speeding up U.S. gas shipments overseas.

  • April 22- Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.

  • WASHINGTON, April 10- U.S. lawmakers investigating General Motors' slow recall of 2.6 million cars are zeroing in on engineers and others who may have been aware of problems with ignition switches linked to at least 13 deaths.

  • WASHINGTON, April 1- General Motors Co CEO Mary Barra on Tuesday called her company's slow response to at least 13 deaths linked to faulty ignition switches "unacceptable," but could not give U.S. lawmakers many answers as to what went wrong as she pointed to an ongoing internal investigation.

  • WASHINGTON, April 1- General Motors CEO Mary Barra, under intense grilling by members of the U.S. Congress, on Tuesday said she found employee statements "disturbing" that cost considerations may have discouraged the prompt replacement of faulty ignition switches now linked to at least 13 fatalities.

  • WASHINGTON/ DETROIT, March 31- A U.S. congressional probe is focusing on why General Motors Co employees repeatedly approved substandard ignition switches linked to at least 13 fatalities, as the automaker on Monday announced another major recall, this time related to power steering issues.

  • WASHINGTON/ DETROIT, March 31- A U.S. congressional probe is focusing on why General Motors employees repeatedly approved ignition switches that failed to meet company standards and how those decisions may have contributed to crashes linked to at least 13 deaths.

  • DETROIT/ WASHINGTON, March 29- When General Motors Co Chief Executive Mary Barra faces Congress next week she will have to explain how the top brass at the biggest U.S. automaker can say they knew nothing for more than a decade about a faulty ignition switch linked to crashes and at least 12 deaths.

  • March 29- Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

  • WASHINGTON, March 25- The U.S. shale gas boom should be used to counteract Russian influence in Europe and on Ukraine, a key senator said on Tuesday, as lawmakers weighed changes to export policy to take into account a shifting geopolitical landscape.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.

  • March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.

  • WASHINGTON, March 21- The U.S. congressional investigation into General Motors Co automobile defects will bring aggressive scrutiny to a company with powerful lobbying clout and strong ties on Capitol Hill.

  • *Senate, House panels to investigate stalling problem. WASHINGTON, March 11- Congress's investigation of a deadly defect in some General Motors cars widened on Tuesday, and a House committee ordered the automaker and a federal regulator to provide details on steps they took to get unsafe cars off the road.

  • WASHINGTON, March 11- A U.S. House of Representatives committee on Tuesday gave General Motors and the National Highway Traffic Safety Administration until March 25 to provide information related to the automaker's recall of vehicles due to safety concerns.

  • E-cig industry on tenterhooks ahead of U.S. regulation Thursday, 20 Feb 2014 | 11:12 AM ET

    WASHINGTON, Feb 20- Lobbyists for electronic cigarette companies have been beating a path to the White House, hoping to prevent the administration from imposing strict, and possibly costly, rules on the burgeoning $2 billion industry.